Kuehn Law Investigates Aardvark Therapeutics Officers and Directors Amid Shareholder Lawsuit
Shareholder litigation firm Kuehn Law, PLLC, is investigating potential breaches of fiduciary duty by Aardvark Therapeutics, Inc. officers and directors. The probe follows claims of misrepresentations in IPO-related filings.
Kuehn Law, PLLC, a law firm specializing in shareholder litigation, has initiated an investigation into certain officers and directors of Aardvark Therapeutics, Inc. (NASDAQ: AARD). The investigation seeks to determine if these individuals breached their fiduciary duties owed to the company's shareholders.
The probe is connected to an ongoing federal securities lawsuit. Allegations in the suit claim that Aardvark Therapeutics misrepresented or failed to disclose crucial information. Specifically, the lawsuit asserts that the company's Initial Public Offering (IPO) related documents filed with the SEC were negligently prepared and contained materially untrue or misleading statements. Furthermore, it is alleged that ARD-101, Aardvark's lead product candidate, proved to be less safe than investors were led to believe, and that the clinical, regulatory, and commercial prospects for ARD-101 were overstated.
Kuehn Law is requesting that current AARD shareholders who purchased their shares prior to March 1, 2025, contact the firm. Interested parties can reach out via email to sophiaanne@kuehn.law or by calling (833) 672-0814. The firm covers all case costs and does not charge its investor clients. The lawyers emphasize the urgency for shareholders to contact them due to potential time limitations for enforcing their rights.
The law firm highlights that shareholder participation is vital for maintaining the integrity and fairness of the financial markets. Further details are available on Kuehn Law's website.